Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
85 Results for "
receptor internalization
" in MedChemExpress (MCE) Product Catalog:
Products (85)
85 Results for "receptor internalization" in MCE Product Catalog:
10
10 Publications Verification
Cat. No.: HY-W008947
CAS No.: 256414-75-2
Target:
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology
SEW2871 is an orally active, potent, highly selective S1P1 (sphingosine-1-phosphate type 1 receptor) agonist, with an EC50 of 13.8 nM. SEW2871 activates ERK, Akt, and Rac signaling pathways and induces S1P1 internalization and recycling. SEW2871 reduces lymphocyte numbers in blood. SEW2871 can be used for the research of diabetes, Alzheimer’s disease, liver fibrosis, and inflammatory responses .
6
6 Cited Publications
Target:
Research Areas:
NUCC-390 is a novel and selective small-molecule CXCR4 receptor agonist. NUCC-390 induces internalization of CXCR4 receptors and acts in an opposite way of AMD3100 (HY-10046) . NUCC-390 promotes nerve recovery of function after neurodegeneration in vivo .
6
6 Cited Publications
Cat. No.: HY-P2106
CAS No.: 1886973-05-2
Target:
Research Areas:
6
6 Cited Publications
Target:
Research Areas:
NUCC-390 dihydrochloride is a novel and selective small-molecule CXCR4 receptor agonist. NUCC-390 dihydrochloride induces internalization of CXCR4 receptors and acts in an opposite way of AMD3100 (HY-10046) . NUCC-390 dihydrochloride promotes nerve recovery of function after neurodegeneration in vivo .
6
6 Cited Publications
Cat. No.: HY-P2106A
Target:
Research Areas:
4
4 Cited Publications
Cat. No.: HY-P2336A
Target:
Research Areas:
3
Category:
Flavonoids Ranunculus japonicus Thunb. Isoflavanones Ranunculaceae Plants Disease Research Fields Cancer
Target:
2
2 Cited Publications
Cat. No.: HY-P2259
CAS No.: 1404188-93-7
Target:
Research Areas:
1
1
1 Cited Publications
Target:
Opioid Receptor G Protein-coupled Receptor Kinase (GRK) Mas-related G-protein-coupled Receptor (MRGPR)
Research Areas:
CCG258747 is a selective GRK2 inhibitor (IC50 = 18 nM) with high selectivity over GRK1, GRK5, PKA, and ROCK1 (518, 83, > 5500, and > 550-fold, respectively). CCG258747 also blocks the internalization of the µ-opioid receptor (MOR). CCG258747 attenuates IgE mediated anaphylaxis by inhibiting GRK2 and FcεRI signaling pathway but activates mast cells via MRGPRX2 and MRGPRB2. CCG258747 can be used to study diseases related to overexpression of GRK2 (such as heart failure, opioid tolerance) .
1
1 Cited Publications
Cat. No.: HY-P11143A
Target:
Research Areas:
Cat. No.: HY-175701
CAS No.: 2810808-95-6
Synonyms: RO7795081; RG6652
Target:
Research Areas:
CT-996 is an orally active GLP-1RA agonist with an EC50 of 0.49 nM. CT-996 reduces the recruitment of β-arrestin and the internalization of GLP-1R. CT-996 suppresses postprandial blood glucose in mice expressing human GLP-1 receptors and enhances glucose-stimulated insulin secretion (GSIS) in obese monkeys during intravenous glucose challenge. CT-996 can be used for the research of type 2 diabetes (T2D) and obesity .
Cat. No.: HY-D2836
Synonyms: FITC-Hyaluronate (MW 1000000)
Cat. No.: HY-P99189
CAS No.: 947687-12-9
Synonyms: IMC-A12; NSC742460
Target:
Research Areas:
ACT-389949 is a first-in-class, potent and selective and agonist of formyl peptide receptor type 2 (FPR2)/Lipoxin A4 receptor (ALX), with an EC50 of 3 nM for FPR2/ALX internalization into monocytes. ACT-389949 has potential for the treatment of inflammatory disorders .
Cat. No.: HY-P5362
Research Areas:
Cat. No.: HY-P9990
CAS No.: 2407378-48-5
Synonyms: BIIB059
Research Areas:
Synonyms: S1p receptor agonist 1
Target:
Research Areas:
Icanbelimod (S1p receptor agonist 1) is a potent and orally active S1P receptor agonist, exhibits an activity of inducing S1P1 internalization (EC50=9.83 nM). Icanbelimod has the potential for the study of arthritis and EAE (experimental autoimmune encephalitis). Icanbelimod is extracted from patent WO2015039587A1, Compound 2.
Cat. No.: HY-P3717
CAS No.: 3031514-44-7
Target:
Research Areas:
Target:
Research Areas:
VU0453379 is a blood-brain barrier permeable GLP-1R positive allosteric modulator (PAM) with an EC50 value of 1.3 μM. VU0453379 potentiates the actions of endogenous GLP-1 and synthetic peptide agonists, and promotes GLP-1 receptor internalization. VU0453379 stimulates insulin secretion from primary mouse islets. VU0453379 enhances the function of endogenous GLP-1R and reverses catalepsy in animal models. VU0453379 is useful for research on Parkinson's disease and type 2 diabetes .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
